News

More than 40% of community-acquired and 70% of hospital-acquired influenza inpatients experienced intrahospital bed transfers during their active infection period.

Anisha Dua, MD, MPH, discusses the mimics, related conditions, and new diseases in the field of vasculitis as it relates to rheumatology.

The most frequent trajectory for children with insomnia symptoms was persistence, followed by remission and waxing-and-waning patterns.

Featuring insights from Dr. Raj Chovatiya, Dr. Karan Lal and more on what can be done to promote inclusivity and improved care for patients with skin of color.

Though the pathogenesis of psoriasis remains vague, recent studies hypothesized that oxidative stress could be involved in the development and perpetuation of psoriasis.

The 2 companies are expected to seek regulatory authorization for the COVID-19 vaccine.

Surgeons were less likely to explore the emotions of parents from racial and ethnic minority groups compared with White parents.

While recent data indicate the potential to reduce opioid overdose mortality rates with naloxone distribution, authors call for increased support for those who witness an overdose.

On this month's episode of Overdrive, Rheumatology Network interviewed Terence Rooney, MD, to discuss the findings of a network meta-analysis that examined the efficacy of guselkumab (TREMFYA) for skin clearance and joint improvements in patients with psoriatic arthritis.

Data show medical students who are URIM were more likely to be in the top quartile of those who experienced exhaustion-related burnout.

Daridorexant 25 mg and 50 mg had the best results in comparison with placebo.

Susan Shenoi, MBBS, MS, discusses the recent developments in pediatric rheumatology as well as new therapies and guidelines for treating juvenile idiopathic arthritis.

Over 21 million children and adolescents aged 12–20 years had received 1 or more doses of a COVID-19 vaccine, amounting to 1 reported case of MIS-C per million vaccinated individuals in this age group.

Vibeke Strand, MD, shares that based on her data, secukinumab is an effective option for treating patients with psoriatic arthritis.

The estimated mean change in body weight from baseline to week 68 was -13.2% in the semaglutide 2.4 mg group versus -2.1% in the placebo group.

the high prevalence of the condition in middle-age and elderly populations has led to frequent updates on the long-term efficacy of current therapies and new investigational agents.

Roy Fleishmann, MD, discusses his Rheumatology Winter Clinical Symposium presentation, “Beyond the package insert: JAK inhibitors (jakinibs): safety issues.”

The Supplemental New Drug Application was based on the results of numerous clinical trials.

The American College of Rheumatology has recently updated its recommendations on COVID-19 booster vaccines. Test your knowledge of the latest advice on COVID-19 boosters and how they should be administered with this quiz.

The esteemed pediatric pulmonologist of Bridge Atlanta Medical Center drops by Lungcast to discuss the disparities that continue to exist in childhood asthma.

Melatonin is seen as the most promising treatment in this patient population.

The expanded indication for the CardioMEMS HF System includes patients with NYHA Class II heart failure and elevated levels of natriuretic peptides.

With the field already booming with capability, a Penn Medicine expert discusses her team's research into finding the right tools for the right patients and clinicians.

Assessing fat free mass and reduced intake are particularly important in identifying malnutrition in patients with inflammatory bowel disease.

An executive with Seqirus discusses the company's work to address age-related flu severity risks.

The Chair of the ACR COVID-19 Vaccine Clinical Guidance Task Force shares what was learned from the Omicron variant and how the recommendations for rheumatologists has been affected by it.

Severe financial strain was associated with a 61% increase in 180-day mortality risk, compared to patients with no strain.

Study provides supportive data to confirm the pathogenic role of NEU1 in proliferative lupus nephritis.

Future clinical trials may be necessary to confirm if 1 treatment is superior to the other to a clinically relevant degree in patients with thyroid eye disease.

Investigators review the current understanding of the role of the BTK pathway and the potential value of pharmacological inhibition of BTK as a therapeutic strategy.